Comparable stake leader
Joseph S. Freedman
SEC ownership of EUPRAXIA PHARMACEUTICALS INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001581178.
Disclosed value leader
Joseph S. Freedman
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- EPRX on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Joseph S. Freedman
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Joseph S. Freedman
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001581178
- Issuer location
- Vancouver
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of EUPRAXIA PHARMACEUTICALS INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Joseph S. Freedman
Disclosed value leader
Joseph S. Freedman
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 9%
13D/G row: Joseph S. Freedman
Showing 1-8 of 50 holder rows.
Quick read
Joseph S. Freedman leads the comparable SEC ownership view at 9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Joseph S. Freedman's linked filing trail.
Comparable ownership
Top 5
Joseph S. Freedman
9%
Beutel, Goodman & Co Ltd.
8%
Robert Disbrow
7%
MANCHESTER MANAGEMENT CO LLC
4.5%
Affinity Asset Advisors, LLC
2.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Joseph S. Freedman |
13D/G
|
9%
|
$47,037,881
5,843,215 shares
|
+$2,495,500 | 13 Mar 2026 |
| Beutel, Goodman & Co Ltd. |
13D/G
13F
Company
|
8%
|
$23,947,504
4,058,899 shares
|
$0 | 30 Sep 2025 |
| Robert Disbrow |
13D/G
|
7%
|
$21,052,085
3,568,150 shares
|
$0 | 30 Sep 2025 |
| MANCHESTER MANAGEMENT CO LLC |
13D/G
JAMES E. BESSER
|
4.5%
|
$19,184,600
2,772,341 shares
|
-$8,600,916 | 30 Jun 2026 |
| Affinity Asset Advisors, LLC |
13F
Company
|
2.7%
|
$10,906,500
1,650,000 shares
|
— | 30 Jun 2026 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
Company
|
2.2%
|
$8,923,599
1,350,015 shares
|
— | 30 Jun 2026 |
| Vivo Capital, LLC |
13F
Company
|
2.2%
|
$8,923,500
1,350,000 shares
|
— | 30 Jun 2026 |
| SCOTIA CAPITAL INC. |
13F
Company
|
2.2%
|
$8,782,272
1,343,726 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Recent insider transactions for EUPRAXIA PHARMACEUTICALS INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.